基本信息
浏览量:2
职业迁徙
个人简介
Dr. Eleni Andreopoulou joined Weill Cornell Medical Center as an Associate Professor of Clinical Medicine specializing in the care and treatment of patients with breast cancer in January 2015. Prior to this appointment she held faculty positions at the Albert Einstein College of Medicine/ Montefiore Medical Center and the University of Texas M.D. Anderson Cancer Center.
Dr. Andreopoulou completed her training in major academic institutions in both Europe and the U.S. After she completed her residency in Internal Medicine at St Bartholomew`s Hospital in London she was awarded a European Society of Medical Oncology fellowship and trained in Medical Oncology at the Royal Marsden Hospital/Institute of Cancer Research in London, UK. She received laboratory training in the signal transduction and molecular pharmacology laboratory studying correlations between drug sensitivity and constitutive gene expression gaining a unique learning experience in a model hybrid clinical/laboratory facility. Subsequently, she completed her fellowship in Hematology and Medical Oncology at the New York University School of Medicine. In addition to intensive and comprehensive clinical training this experience was key to her understanding of the complexities in preclinical and clinical evaluation of anticancer drugs and established a strong foundation in her career. In addition to her active clinical practice her strength to the Weill Cornell Medical Center team is her demonstrated passion for biomarker-driven clinical trials, pharmacogenomic predictors of chemoresistance, chemosensitivity, and endocrine sensitivity for early and advanced stage breast cancer. Most importantly, she conceptualized and established a prospective bio-repository in breast cancer providing a crucial foundation for precision medicine research. She assembled this multidisciplinary team effort at Einstein/Montefiore and in collaboration with scientists used the bio specimens to probe one of the most perplexing challenges in modern clinical oncology – the issue of drug resistance and its relationship to chemotherapy-mediated dormancy.
At Weill Cornell Medical Center, Dr. Andreopoulou continues to actively facilitate the interface between basic and applied research, and has a special interest in individualized patient treatment. Her main research interest is biomarker-based patient selection in early phase development to fast track drug development of biologics and targeted therapy to effectively treat breast cancer while sparing patients from unnecessary toxicity. Her focus is next generation -oncology trials and incorporating technology in drug development. Her goal, in collaboration with scientists, is to explore the relationship between cancer treatment, neoplastic cells and the immune system in order to improve understanding of the determinants of response to therapy. This has the potential to contribute critical information for future testing of combinations of immunotherapy and chemotherapy in breast cancer treatment.
She is an active investigator of several clinical trials of novel therapeutic approaches in advanced disease including her leadership role as a principal investigator in development of agents sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute.
Dr. Andreopoulou has published over 40 peer review articles, reviews, editorials and book chapters and has been an invited speaker at international and national conferences. She is a member of several scientific organizations including the American Society of Clinical Oncology, the American Association of Cancer Research and the Royal Society of Medicine. She has also been active with Breast Cancer awareness programs covering screening and prevention with a particular focus on underserved minorities. She is also an active member of the American Women`s Medical Association.
Dr. Andreopoulou completed her training in major academic institutions in both Europe and the U.S. After she completed her residency in Internal Medicine at St Bartholomew`s Hospital in London she was awarded a European Society of Medical Oncology fellowship and trained in Medical Oncology at the Royal Marsden Hospital/Institute of Cancer Research in London, UK. She received laboratory training in the signal transduction and molecular pharmacology laboratory studying correlations between drug sensitivity and constitutive gene expression gaining a unique learning experience in a model hybrid clinical/laboratory facility. Subsequently, she completed her fellowship in Hematology and Medical Oncology at the New York University School of Medicine. In addition to intensive and comprehensive clinical training this experience was key to her understanding of the complexities in preclinical and clinical evaluation of anticancer drugs and established a strong foundation in her career. In addition to her active clinical practice her strength to the Weill Cornell Medical Center team is her demonstrated passion for biomarker-driven clinical trials, pharmacogenomic predictors of chemoresistance, chemosensitivity, and endocrine sensitivity for early and advanced stage breast cancer. Most importantly, she conceptualized and established a prospective bio-repository in breast cancer providing a crucial foundation for precision medicine research. She assembled this multidisciplinary team effort at Einstein/Montefiore and in collaboration with scientists used the bio specimens to probe one of the most perplexing challenges in modern clinical oncology – the issue of drug resistance and its relationship to chemotherapy-mediated dormancy.
At Weill Cornell Medical Center, Dr. Andreopoulou continues to actively facilitate the interface between basic and applied research, and has a special interest in individualized patient treatment. Her main research interest is biomarker-based patient selection in early phase development to fast track drug development of biologics and targeted therapy to effectively treat breast cancer while sparing patients from unnecessary toxicity. Her focus is next generation -oncology trials and incorporating technology in drug development. Her goal, in collaboration with scientists, is to explore the relationship between cancer treatment, neoplastic cells and the immune system in order to improve understanding of the determinants of response to therapy. This has the potential to contribute critical information for future testing of combinations of immunotherapy and chemotherapy in breast cancer treatment.
She is an active investigator of several clinical trials of novel therapeutic approaches in advanced disease including her leadership role as a principal investigator in development of agents sponsored by the Cancer Therapy Evaluation Program at the National Cancer Institute.
Dr. Andreopoulou has published over 40 peer review articles, reviews, editorials and book chapters and has been an invited speaker at international and national conferences. She is a member of several scientific organizations including the American Society of Clinical Oncology, the American Association of Cancer Research and the Royal Society of Medicine. She has also been active with Breast Cancer awareness programs covering screening and prevention with a particular focus on underserved minorities. She is also an active member of the American Women`s Medical Association.
研究兴趣
论文共 157 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Translational Breast Cancer Research (2024): 10-10
Letizia Pontolillo,Eleonora Nicolò, Laura Munoz Arcos,Carolina Reduzzi,Mara Serena Serafini, Amanda Kaylan Strickland, Nadia Bayou,Jeannine Donahue,Elisabetta Molteni,Lorenzo Gerratana,Diana Giannarelli,Eleni Andreopoulou,
Cancer Researchno. 9_Supplement (2024): PO3-14
FRONTIERS IN ONCOLOGY (2023): 1061789-1061789
Eleonora Nicolò,Mara Serena Serafini,Laura Munoz-Arcos, Letizia Pontolillo,Elisabetta Molteni, Nadia Bayou,Eleni Andreopoulou,Giuseppe Curigliano,Carolina Reduzzi,Massimo Cristofanilli
The Journal of Liquid Biopsy (2023): 100117-100117
引用0浏览0引用
0
0
Journal of clinical oncology : official journal of the American Society of Clinical Oncologyno. 24 (2023): 4004-+
Cancer Researchno. 7_Supplement (2023): 3437-3437
引用0浏览0引用
0
0
JOURNAL OF CLINICAL ONCOLOGYno. 16 (2023): 575-575
引用1浏览0引用
1
0
Majd Al Assaad,Hui-Hsuan Kuo,Jones Nauseef,Max F. Levine,Gunes Gundem,Juan S. Medina-Martinez,Jyothi Manohar,Michael Sigouros, Ahmed Elsaeed,David Wilkes,Elli Papaemmanuil, Eloise Chapman,
CANCER RESEARCHno. 7 (2023)
引用0浏览0引用
0
0
Sherry Shen, Erica Salehi,Azeez Farooki,James Flory, Dominiq Williams,Andrea Carpio, Cassandra Chang,Mario E. Lacouture,Eleni Andreopoulou,Sagar D. Sardesai,Komal L. Jhaveri,Lewis Clayton Cantley,
引用0浏览0引用
0
0
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn